Full-Time
AI & Data Science Lead
Updated on 9/7/2026
AstraZeneca
10,001+ employees
Global pharmaceutical company developing prescription medicines
No salary listed
La Défense, France
In Person
Bachelor's
 Project & Program Management (1) |
|---|
Get referred to AstraZeneca
See people who can refer or advise you
- A higher-education degree equivalent to Bac+5 in data science, artificial intelligence, computer science, or a related field.
- Confirmed experience leading Data or artificial intelligence projects or initiatives.
- Fluency in written and spoken French and English.
- Good understanding of data science, machine learning, and artificial intelligence applications.
- Ability to analyze and interpret data, including data from data science models, to derive useful insights for decision-making and performance evaluation.
- Ability to identify, prioritize, and lead high-value initiatives aligned with business needs.
- Ability to work cross-functionally, coordinate varied stakeholders, and facilitate decision-making.
- Sensitivity to artificial intelligence governance, compliance, risk management, and ethics issues.
- Analytical mindset, rigor, autonomy, and results orientation.
- Structure, prioritize, and arbitrate the portfolio of artificial intelligence initiatives in alignment with AstraZeneca France's strategic and operational priorities.
- Coordinate with global teams to consolidate a local France roadmap.
- Prepare the roadmap for arbitration by IBEX management and the executive committee.
- Work closely with business teams to identify, evaluate, and prioritize artificial intelligence use cases.
- Lead artificial intelligence initiatives from ideation through delivery by coordinating multidisciplinary teams and business experts.
- Methodologically challenge proposals from local suppliers and solutions developed by global teams, including their performance metrics, validation robustness, bias or overfitting risks, and suitability for the business use case.
- Keep sponsors and stakeholders informed about initiative progress, successes, challenges, and lessons learned.
- Monitor external advances in artificial intelligence, including generative and agentic artificial intelligence and emerging fields.
- Share relevant artificial intelligence information with internal stakeholders.
- Experience in an international, matrixed, or regulated environment.
- Knowledge of the healthcare or pharmaceutical industry.
AstraZeneca develops and markets prescription medicines and vaccines for global health, focusing on oncology, cardiovascular/metabolic, respiratory, and infectious diseases. Its products work by targeting specific biological pathways or cells to treat diseases or prevent infections, using small-molecule drugs, biologics, and vaccines. The company differentiates itself through its dual heritage from Sweden and the UK, a broad pipeline, and strong R&D with collaborations to move from discovery to patient access across multiple therapeutic areas. Its goal is to improve people’s health by discovering, developing, and delivering medicines and vaccines worldwide.
Company Size
10,001+
Company Stage
IPO
Headquarters
Cambridge, United Kingdom
Founded
1913
Get referred to AstraZeneca
See people who can refer or advise you
Simplify's Take
What believers are saying
- EU approved Enhertu plus pertuzumab on September 1, 2026, unlocking another breast-cancer line.
- Amgen and AstraZeneca’s DeLLphi-305 met overall-survival goals for Imdelltra plus Imfinzi.
- AstraZeneca committed £300 million in April 2026 to Cambridge and Macclesfield expansion.
What critics are saying
- Reuters on August 17, 2026 said AstraZeneca ended volrustomig’s lung-cancer trial after futility.
- China indicted Leon Wang and AstraZeneca’s local unit in February 2026; trial risk persists.
- Forxiga faces patent losses in Poland, Portugal, Australia, and 2027 generic-launch pressure.
What makes AstraZeneca unique
- AstraZeneca’s 2026 cancer franchise spans Imfinzi, Tagrisso, Enhertu, and Datroway globally.
- Its UK-Sweden operating base supports Cambridge and Macclesfield R&D plus manufacturing.
- Daiichi Sankyo and Amgen partnerships broaden AstraZeneca’s reach without full internal capital burden.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 2%2 year growth
↑ 4%Jim Cramer stated on Mad Money that he is not investing in AstraZeneca, comparing it to Novartis and expressing concerns about missed clinical trials. He believes the company's COPD programme is insufficient to change his view. AstraZeneca reported second-quarter revenue of $15.38 billion, up 6.4% year-on-year, with adjusted earnings per share of $2.63 beating estimates. Growth was driven by oncology and rare disease treatments, offsetting generic competition. However, the company faces significant challenges. The drug anselamimab failed its primary endpoint in a Phase III trial, whilst datopotamab deruxtecan delivered mixed results in lung cancer studies. AstraZeneca's blockbuster drug Farxiga will face a 68% Medicare price reduction from 2026 under the Inflation Reduction Act. The company also contends with regulatory investigations in China involving senior executives.
Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.
Drug giant AstraZeneca has agreed to buy KuDOS Pharmaceuticals, a UK biotech company, for $210mn (£120m).
AstraZeneca shares declined approximately 0.7% to $161.51 despite positive late-stage trial results for Imfinzi in treating extensive-stage small-cell lung cancer. The 563-patient DeLLphi-305 trial met its primary overall-survival goal when Imfinzi was combined with Amgen's Imdelltra, also improving progression-free survival and response rates with no new safety concerns. However, the companies have not released numerical survival data, leaving investors unable to assess the treatment's competitive strength. Imfinzi generated $6.06 billion in 2025, whilst oncology represented approximately 46% of AstraZeneca's $30.7 billion first-half 2026 revenue. The shares now trade 10.72% below their $180.91 valuation estimate. AstraZeneca must share economics with Amgen and demonstrate that the treatment's added complexity can convert into meaningful sales growth.
First Oncology Summit in Lebanon hosted by AstraZeneca brings together regional experts to advance the Future of Cancer Care. September 7, 2026 Beirut, 7 September 2026: The first Oncology Summit hosted by AstraZeneca in Lebanon under the theme "Leading the Future in Cancer Care" brought together leading oncology experts from Lebanon and Libya, alongside international faculty members, for two days of scientific exchange and collaboration focused on advancing cancer care and improving patient outcomes. The summit featured discussions on evolving standards of care, emerging scientific advances, and multidisciplinary approaches across lung cancer, gastrointestinal cancers, breast cancer, and ovarian cancer. "Scientific meetings such as this are essential to advancing oncology practice," said Dr. Arafat Tfayli, President of the Committee Responsible for Implementing Lebanon's National Cancer Control Plan. "They allow healthcare professionals to exchange experiences, discuss the latest evidence, and learn from regional and international experts. By strengthening collaboration and sharing knowledge, we can continue to elevate the quality of care available to patients across our region." "The challenges we face in cancer care are shared across many countries, and so too are the opportunities for progress," said Dr. Abdelmnam Elbarathi, Director of Tripoli Cancer Center, speaking on behalf of the Lybian delegation. "Bringing together experts from Libya and Lebanon creates meaningful opportunities for collaboration, learning, and professional exchange that can ultimately contribute to better care for patients. We look forward to strengthening these connections and continuing to work together to advance oncology practice throughout the region." The landmark event underscored AstraZeneca's commitment to supporting the oncology community through innovation, science, and partnerships, while reinforcing Lebanon's role as a regional platform for medical excellence and scientific dialogue. "Lebanon has long been recognized for its medical expertise, and we are proud to contribute to its role as a hub for scientific leadership and innovation," said Agnar Aboujaoude, Country Director, AstraZeneca Lebanon, who emphasized the power of collaboration in shaping the future of oncology care. "We are proud to bring together distinguished oncology experts from Lebanon, Libya, and the international scientific community around a shared purpose: improving the lives of patients with cancer. By fostering scientific exchange and regional collaboration, we can help accelerate the adoption of best practices, strengthen healthcare ecosystems, and ultimately bring new hope to patients and their families." The summit provided a platform for healthcare professionals to exchange knowledge, review emerging evidence, discuss real-world clinical experiences, and explore innovative approaches that are helping redefine cancer care worldwide. Throughout the discussions, participants examined the evolving oncology landscape and the opportunities to improve outcomes through earlier diagnosis, precision medicine, multidisciplinary care, and continued scientific advancement. "At AstraZeneca, our ambition is to eliminate cancer as a cause of death," said Mark Farid, Oncology Commercial Director for Near East & Maghreb at AstraZeneca, highlighting the company's long-term commitment to transforming cancer care through scientific innovation. "We continue to invest in one of the industry's broadest oncology portfolios and pipelines, advancing innovative science across multiple tumour types and treatment modalities. Through collaboration with healthcare professionals, researchers, and healthcare systems, we are working to transform outcomes and bring patients closer to a future where cancer can be detected earlier, treated more effectively, and, ultimately, cured." About AstraZeneca: AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.